Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy : JANUS 1 and 2 randomized phase III studies

Thumbnail Image
Files
Ruxolitinib + capecitabine in advanced-metastatic pancreatic cancer after disease progression-intolerance to first-line therapy JANUS 1 and 2 randomized phase III studies.pdf(3.28 KB)
Date
2018
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Description
Keywords
Citation
URI
https://doi.org/10.1007/s10637-018-0580-2
 https://repositorio.uc.cl/handle/11534/48463
Collections
Artículos de revistas